This document is an excerpt from the EUR-Lex website
Document 62017CN0443
Case C-443/17: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents
Case C-443/17: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents
Case C-443/17: Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents
OJ C 309, 18.9.2017, p. 30–31
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
18.9.2017 |
EN |
Official Journal of the European Union |
C 309/30 |
Reference for a preliminary ruling from High Court of Justice (Chancery Division) (United Kingdom) made on 24 July 2017 — Abraxis Bioscience LLC v Comptroller General of Patents
(Case C-443/17)
(2017/C 309/41)
Language of the case: English
Referring court
High Court of Justice (Chancery Division)
Parties to the main proceedings
Applicant: Abraxis Bioscience LLC
Defendant: Comptroller General of Patents
Question referred
Is Article 3(d) of the SPC Regulation (1) to be interpreted as permitting the grant of an SPC where the marketing authorisation referred to in Article 3(b) is the first authorisation within the scope of the basic patent to place the product on the market as a medicinal product and where the product is a new formulation of an old active ingredient?
(1) Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ L 152, p. 1)